Amgen (AMGN) · Fiscal Q3 2026 · Form 8-K filed Nov 3, 2026
| Key figure | This quarter |
|---|---|
| Revenue | $10.4 billion |
| Net income (GAAP) | $3.86 billion |
| Diluted EPS (GAAP) | $7.08 |
| Operating margin (GAAP) | 37.5% |
Results
Total revenues rose 8% to $10.4 billion, the company said, compared with the third quarter of 2025.
Net income was $3,864 million. GAAP diluted EPS was $7.08, up from $6.45 in the same quarter a year earlier.
On a GAAP basis, this was the strongest quarter in the recent run shown: EPS of $7.08 compares with $4.37 in the second quarter of 2026 and $3.34 in the first.
Margins and cash flow
Operating margin as a percentage of product sales increased 9.9 percentage points to 37.5%.
What else stood out
Repatha sales increased 37% year-over-year to $1,085 million, primarily driven by volume growth.
IMDELLTRA/IMDYLLTRA sales increased 128% year-over-year to $406 million, also driven by volume growth.
The company declared a third quarter 2026 dividend of $2.52 per share on July 30, 2026, paid September 11, 2026 to stockholders of record as of August 21, 2026, a 6% increase from the same period in 2025.
No shares were repurchased under the stock repurchase program during the quarter.
Revenue has moved from $8.618 billion in the first quarter of 2026 to $10.054 billion in the second and $10.365 billion in the third, per the XBRL history.
